MONTREAL, Nov. 5 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB)
announced today that dosing is complete for its Phase II clinical trial of
PC-DAC(TM):Exendin-4. This Phase II trial was a randomized, double-blind,
placebo-controlled, multiple dose study that evaluated the efficacy and safety
of three months of weekly injections of PC-DAC(TM):Exendin-4 in patients with
Type 2 diabetes not adequately controlled by metformin monotherapy. The trial
enrolled approximately 120 evaluable patients randomized to one of three
parallel treatment groups: a 1.5mg fixed-dose weekly cohort; a 1.5mg weekly
dose titrating to 2mg at the 5th week cohort; and a placebo group. Top line
data from the trial will be announced in December, 2008.
